Esperion Free Cash Flow vs Stock Based Compensation Analysis

ESPR Stock

USD 2.17 0.02 0.93%

Esperion Therapeutics financial indicator trend analysis is much more than just examining Esperion Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Esperion Therapeutics is a good investment. Please check the relationship between Esperion Therapeutics Free Cash Flow and its Stock Based Compensation accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.

Free Cash Flow vs Stock Based Compensation

Free Cash Flow vs Stock Based Compensation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Esperion Therapeutics Free Cash Flow account and Stock Based Compensation. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Esperion Therapeutics' Free Cash Flow and Stock Based Compensation is -0.69. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Stock Based Compensation in the same time period over historical financial statements of Esperion Therapeutics, assuming nothing else is changed. The correlation between historical values of Esperion Therapeutics' Free Cash Flow and Stock Based Compensation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Esperion Therapeutics are associated (or correlated) with its Stock Based Compensation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Stock Based Compensation has no effect on the direction of Free Cash Flow i.e., Esperion Therapeutics' Free Cash Flow and Stock Based Compensation go up and down completely randomly.

Correlation Coefficient

-0.69

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Most indicators from Esperion Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Esperion Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.As of 01/07/2025, Selling General Administrative is likely to grow to about 153.3 M, while Issuance Of Capital Stock is likely to drop slightly above 28.9 M.

	2024	2025 (projected)
Interest Income	4.0M	3.5M
Reconciled Depreciation	287.5K	432.3K

Interest Income Reconciled Depreciation

Esperion Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Non Currrent Assets Other	Intangible Assets	Short Term Investments	Other Liab
Total Assets		0.29	0.45	0.38	-0.44	0.44	0.05	-0.54	0.48	0.74	0.51	0.73	0.5	0.32	0.48	0.72	0.26	0.47	0.28	0.98	0.08	0.36	-0.19	-0.41	0.4	-0.67
Short Long Term Debt Total	0.29		0.94	0.95	-0.42	0.75	0.94	-0.87	0.56	0.27	-0.27	0.27	0.91	0.95	0.93	0.29	0.19	0.95	0.82	0.37	0.94	0.97	0.45	-0.18	-0.42	-0.72
Other Current Liab	0.45	0.94		0.99	-0.59	0.81	0.81	-0.95	0.76	0.46	-0.3	0.45	0.93	0.94	0.93	0.54	0.26	0.96	0.83	0.55	0.83	0.94	0.38	-0.25	-0.33	-0.79
Total Current Liabilities	0.38	0.95	0.99		-0.55	0.8	0.84	-0.93	0.78	0.39	-0.34	0.39	0.91	0.95	0.91	0.48	0.26	0.94	0.85	0.49	0.86	0.94	0.36	-0.25	-0.34	-0.74
Total Stockholder Equity	-0.44	-0.42	-0.59	-0.55		-0.45	-0.2	0.73	-0.63	-0.68	0.38	-0.68	-0.56	-0.36	-0.69	-0.89	-0.21	-0.67	-0.26	-0.58	-0.36	-0.41	-0.48	0.16	0.32	0.52
Property Plant And Equipment Net	0.44	0.75	0.81	0.8	-0.45		0.55	-0.71	0.74	0.66	-0.29	0.66	0.61	0.67	0.77	0.51	0.26	0.79	0.95	0.54	0.6	0.66	0.45	-0.03	-0.45	-0.52
Net Debt	0.05	0.94	0.81	0.84	-0.2	0.55		-0.73	0.38	-0.07	-0.29	-0.07	0.82	0.92	0.77	0.01	0.17	0.8	0.69	0.1	0.95	0.93	0.35	-0.09	-0.36	-0.59
Retained Earnings	-0.54	-0.87	-0.95	-0.93	0.73	-0.71	-0.73		-0.74	-0.5	0.24	-0.5	-0.94	-0.87	-0.94	-0.66	-0.28	-0.95	-0.67	-0.64	-0.77	-0.9	-0.35	0.29	0.25	0.84
Accounts Payable	0.48	0.56	0.76	0.78	-0.63	0.74	0.38	-0.74		0.58	-0.32	0.58	0.58	0.6	0.62	0.7	0.26	0.66	0.69	0.6	0.41	0.57	0.14	-0.26	-0.14	-0.55
Cash	0.74	0.27	0.46	0.39	-0.68	0.66	-0.07	-0.5	0.58		0.02	1.0	0.35	0.19	0.54	0.85	0.11	0.52	0.43	0.81	0.08	0.23	0.34	-0.27	-0.2	-0.46
Non Current Assets Total	0.51	-0.27	-0.3	-0.34	0.38	-0.29	-0.29	0.24	-0.32	0.02		0.02	-0.1	-0.23	-0.25	-0.09	0.03	-0.27	-0.34	0.32	-0.39	-0.18	-0.52	-0.18	0.69	-0.11
Cash And Short Term Investments	0.73	0.27	0.45	0.39	-0.68	0.66	-0.07	-0.5	0.58	1.0	0.02		0.35	0.19	0.54	0.85	0.1	0.51	0.43	0.81	0.08	0.23	0.34	-0.27	-0.2	-0.46
Common Stock Total Equity	0.5	0.91	0.93	0.91	-0.56	0.61	0.82	-0.94	0.58	0.35	-0.1	0.35		0.94	0.92	0.48	0.2	0.93	0.62	0.57	0.82	0.97	0.27	-0.3	-0.17	-0.9
Common Stock Shares Outstanding	0.32	0.95	0.94	0.95	-0.36	0.67	0.92	-0.87	0.6	0.19	-0.23	0.19	0.94		0.85	0.28	0.22	0.88	0.78	0.39	0.89	0.99	0.23	-0.24	-0.24	-0.78
Non Current Liabilities Total	0.48	0.93	0.93	0.91	-0.69	0.77	0.77	-0.94	0.62	0.54	-0.25	0.54	0.92	0.85		0.59	0.23	1.0	0.72	0.58	0.84	0.89	0.53	-0.21	-0.41	-0.78
Other Current Assets	0.72	0.29	0.54	0.48	-0.89	0.51	0.01	-0.66	0.7	0.85	-0.09	0.85	0.48	0.28	0.59		0.27	0.58	0.29	0.82	0.15	0.31	0.23	-0.28	-0.05	-0.53
Other Stockholder Equity	0.26	0.19	0.26	0.26	-0.21	0.26	0.17	-0.28	0.26	0.11	0.03	0.1	0.2	0.22	0.23	0.27		0.24	0.22	0.28	0.23	0.19	-0.08	0.06	0.18	-0.05
Total Liab	0.47	0.95	0.96	0.94	-0.67	0.79	0.8	-0.95	0.66	0.52	-0.27	0.51	0.93	0.88	1.0	0.58	0.24		0.76	0.57	0.86	0.92	0.5	-0.22	-0.4	-0.79
Property Plant And Equipment Gross	0.28	0.82	0.83	0.85	-0.26	0.95	0.69	-0.67	0.69	0.43	-0.34	0.43	0.62	0.78	0.72	0.29	0.22	0.76		0.37	0.69	0.74	0.38	-0.04	-0.45	-0.5
Total Current Assets	0.98	0.37	0.55	0.49	-0.58	0.54	0.1	-0.64	0.6	0.81	0.32	0.81	0.57	0.39	0.58	0.82	0.28	0.57	0.37		0.16	0.42	-0.09	-0.4	0.27	-0.7
Short Term Debt	0.08	0.94	0.83	0.86	-0.36	0.6	0.95	-0.77	0.41	0.08	-0.39	0.08	0.82	0.89	0.84	0.15	0.23	0.86	0.69	0.16		0.89	0.46	-0.21	-0.47	-0.54
Common Stock	0.36	0.97	0.94	0.94	-0.41	0.66	0.93	-0.9	0.57	0.23	-0.18	0.23	0.97	0.99	0.89	0.31	0.19	0.92	0.74	0.42	0.89		0.3	-0.24	-0.26	-0.82
Non Currrent Assets Other	-0.19	0.45	0.38	0.36	-0.48	0.45	0.35	-0.35	0.14	0.34	-0.52	0.34	0.27	0.23	0.53	0.23	-0.08	0.5	0.38	-0.09	0.46	0.3		0.17	-0.92	-0.13
Intangible Assets	-0.41	-0.18	-0.25	-0.25	0.16	-0.03	-0.09	0.29	-0.26	-0.27	-0.18	-0.27	-0.3	-0.24	-0.21	-0.28	0.06	-0.22	-0.04	-0.4	-0.21	-0.24	0.17		-0.18	0.32
Short Term Investments	0.4	-0.42	-0.33	-0.34	0.32	-0.45	-0.36	0.25	-0.14	-0.2	0.69	-0.2	-0.17	-0.24	-0.41	-0.05	0.18	-0.4	-0.45	0.27	-0.47	-0.26	-0.92	-0.18		-0.01
Other Liab	-0.67	-0.72	-0.79	-0.74	0.52	-0.52	-0.59	0.84	-0.55	-0.46	-0.11	-0.46	-0.9	-0.78	-0.78	-0.53	-0.05	-0.79	-0.5	-0.7	-0.54	-0.82	-0.13	0.32	-0.01

Click cells to compare fundamentals

Esperion Therapeutics Account Relationship Matchups

Esperion Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	353.3M	381.6M	247.9M	205.8M	236.7M	181.9M
Short Long Term Debt Total	185.4M	260.2M	260.9M	540.9M	622.1M	653.2M
Other Current Liab	37.8M	37.4M	40.6M	62.7M	72.1M	75.7M
Total Current Liabilities	94.1M	73.4M	92.3M	156.2M	179.7M	188.6M
Total Stockholder Equity	(838.8M)	(1.1B)	(1.3B)	(455.0M)	(409.5M)	(389.0M)
Property Plant And Equipment Net	7.3M	2.6M	1.2M	4.7M	5.4M	5.6M
Net Debt	(119.6M)	51.3M	136.2M	458.7M	527.5M	553.9M
Retained Earnings	(838.8M)	(1.1B)	(1.3B)	(1.5B)	(1.4B)	(1.3B)
Accounts Payable	52.0M	17.6M	23.0M	31.7M	36.5M	38.3M
Cash	305.0M	208.9M	124.8M	82.2M	94.6M	91.3M
Non Current Assets Total	7.4M	52.6M	1.3M	4.7M	5.4M	5.2M
Cash And Short Term Investments	305.0M	208.9M	124.8M	82.2M	94.6M	91.8M
Common Stock Shares Outstanding	27.5M	28.9M	66.4M	103.1M	118.6M	124.5M
Liabilities And Stockholders Equity	(389.4M)	(527.8M)	(768.3M)	205.8M	185.2M	194.5M
Non Current Liabilities Total	355.3M	505.2M	479.4M	504.6M	580.3M	609.3M
Other Current Assets	12.4M	12.3M	10.9M	4.7M	5.4M	4.6M
Other Stockholder Equity	742.7M	909.4M	1.0B	1.1B	1.3B	1.3B
Total Liab	449.4M	578.5M	571.7M	660.8M	759.9M	797.9M
Property Plant And Equipment Gross	7.3M	664K	164K	6.7M	7.7M	8.1M
Total Current Assets	345.9M	329.0M	246.7M	201.1M	231.2M	160.4M
Short Term Debt	8.0M	12.7M	25.1M	36.4M	41.8M	43.9M
Non Currrent Assets Other	(7.4M)	50M	(42.1M)	(1.0)	(0.9)	(0.94)
Long Term Debt	179.4M	258.3M	259.9M	261.6M	300.8M	315.9M
Property Plant Equipment	1.1M	1.3M	664K	164K	188.6K	179.2K
Current Deferred Revenue	1.7M	5.7M	3.5M	25.4M	29.2M	30.7M
Net Tangible Assets	19.9M	(96.2M)	(196.9M)	(323.8M)	(291.4M)	(276.8M)
Retained Earnings Total Equity	(695.3M)	(838.8M)	(1.1B)	(1.3B)	(1.2B)	(1.1B)
Capital Surpluse	715.2M	797.7M	964.4M	1.1B	1.2B	676.3M
Long Term Investments	34.7M	0.0	50.4M	42.1M	37.9M	29.2M
Net Invested Capital	83.2M	61.3M	(63.9M)	(193.4M)	(174.1M)	(165.4M)

Pair Trading with Esperion Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Esperion Stock

0.66

BMY

Bristol Myers Squibb Aggressive Push

Pair Corr

Moving against Esperion Stock

0.57	EVOK	Evoke Pharma	Pair Corr
0.57	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.37	UPC	Universe Pharmaceuticals	Pair Corr
0.36	FOLD	Amicus Therapeutics	Pair Corr
0.33	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr

The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.

The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Esperion Stock Analysis

When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC